Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
2485
mi
from 98109
Boston, MA
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
1922
mi
from 98109
Berkley, MI
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
1922
mi
from 98109
Berkley, MI
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
2375
mi
from 98109
Camden, NJ
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
2375
mi
from 98109
Camden, NJ
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
2391
mi
from 98109
East Orange, NJ
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
2391
mi
from 98109
East Orange, NJ
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
2393
mi
from 98109
Newark, NJ
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
2393
mi
from 98109
Newark, NJ
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
2402
mi
from 98109
Bronx, NY
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
2402
mi
from 98109
Bronx, NY
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
2341
mi
from 98109
Durham, NC
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
2341
mi
from 98109
Durham, NC
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
2274
mi
from 98109
Huntersville, NC
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
2274
mi
from 98109
Huntersville, NC
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
2279
mi
from 98109
Winston Salem, NC
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
2279
mi
from 98109
Winston Salem, NC
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
2020
mi
from 98109
Cleveland, OH
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
2020
mi
from 98109
Cleveland, OH
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
147
mi
from 98109
Portland, OR
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
147
mi
from 98109
Portland, OR
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
2373
mi
from 98109
Philadelphia, PA
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
2373
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
2321
mi
from 98109
Columbia, SC
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
2321
mi
from 98109
Columbia, SC
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
1775
mi
from 98109
Austin, TX
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
1775
mi
from 98109
Austin, TX
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
1682
mi
from 98109
Dallas, TX
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
1682
mi
from 98109
Dallas, TX
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
1937
mi
from 98109
Galveston, TX
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
1937
mi
from 98109
Galveston, TX
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
1890
mi
from 98109
Houston, TX
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
1890
mi
from 98109
Houston, TX
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
1779
mi
from 98109
Longview, TX
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
1779
mi
from 98109
Longview, TX
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
2421
mi
from 98109
Hampton, VA
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
2421
mi
from 98109
Hampton, VA
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
2
mi
from 98109
Seattle, WA
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
2
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
Clinical Research Facility
1681
mi
from 98109
Milwaukee, WI
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
Clinical Research Facility
1681
mi
from 98109
Milwaukee, WI
Click here to add this to my saved trials
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated:  7/1/2015
6918
mi
from 98109
Buenos Aires,
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Status: Enrolling
Updated: 7/1/2015
6918
mi
from 98109
Buenos Aires,
Click here to add this to my saved trials
Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1
Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency (XSCID): A Phase 2 Study Assessing Safety and Clinical Response to Treatment With Insulin-like Growth Factor-1 (IGF-1)
Status: Enrolling
Updated:  7/2/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
2315
mi
from 98109
Bethesda, MD
Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1
Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency (XSCID): A Phase 2 Study Assessing Safety and Clinical Response to Treatment With Insulin-like Growth Factor-1 (IGF-1)
Status: Enrolling
Updated: 7/2/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
2315
mi
from 98109
Bethesda, MD
Click here to add this to my saved trials
Drug Drug Interaction of BI 201335 and Tenofovir
Effect of Multiple Dosing With 240 mg BID BI 201335 on the Steady State Pharmacokinetics of 300mg QD Tenofovir and Effect of Multiple Dosing With 300mg QD Tenofovir on Steady State BI 201335 Pharmacokinetics in Healthy Male and Female Volunteers
Status: Enrolling
Updated:  7/3/2015
1218.74.01050 Boehringer Ingelheim Investigational Site
2117
mi
from 98109
Buffalo, NY
Drug Drug Interaction of BI 201335 and Tenofovir
Effect of Multiple Dosing With 240 mg BID BI 201335 on the Steady State Pharmacokinetics of 300mg QD Tenofovir and Effect of Multiple Dosing With 300mg QD Tenofovir on Steady State BI 201335 Pharmacokinetics in Healthy Male and Female Volunteers
Status: Enrolling
Updated: 7/3/2015
1218.74.01050 Boehringer Ingelheim Investigational Site
2117
mi
from 98109
Buffalo, NY
Click here to add this to my saved trials
Exploring HIV Entry Blockade as a Pre-exposure Prophylaxis Strategy in Women
Exploring HIV Entry Blockade as a Pre-exposure Prophylaxis Strategy in Women
Status: Enrolling
Updated:  7/8/2015
Grady Infectious Diseases Program
2178
mi
from 98109
Atlanta, GA
Exploring HIV Entry Blockade as a Pre-exposure Prophylaxis Strategy in Women
Exploring HIV Entry Blockade as a Pre-exposure Prophylaxis Strategy in Women
Status: Enrolling
Updated: 7/8/2015
Grady Infectious Diseases Program
2178
mi
from 98109
Atlanta, GA
Click here to add this to my saved trials
Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV
An Open Label, On-Treatment Trial to Assess the Effect of HIV-1 Coinfection on Therapeutic Responses Using Boceprevir, Peg-Interferon-alfa-2b and Ribavirin in HCV Genotype 1, IFN Treatment-Naive Subjects With or Without HIV-1
Status: Enrolling
Updated:  7/9/2015
Unity Health Care, Inc./DC General
2322
mi
from 98109
Washington, DC,
Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV
An Open Label, On-Treatment Trial to Assess the Effect of HIV-1 Coinfection on Therapeutic Responses Using Boceprevir, Peg-Interferon-alfa-2b and Ribavirin in HCV Genotype 1, IFN Treatment-Naive Subjects With or Without HIV-1
Status: Enrolling
Updated: 7/9/2015
Unity Health Care, Inc./DC General
2322
mi
from 98109
Washington, DC,
Click here to add this to my saved trials
Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV
An Open Label, On-Treatment Trial to Assess the Effect of HIV-1 Coinfection on Therapeutic Responses Using Boceprevir, Peg-Interferon-alfa-2b and Ribavirin in HCV Genotype 1, IFN Treatment-Naive Subjects With or Without HIV-1
Status: Enrolling
Updated:  7/9/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
2315
mi
from 98109
Bethesda, MD
Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV
An Open Label, On-Treatment Trial to Assess the Effect of HIV-1 Coinfection on Therapeutic Responses Using Boceprevir, Peg-Interferon-alfa-2b and Ribavirin in HCV Genotype 1, IFN Treatment-Naive Subjects With or Without HIV-1
Status: Enrolling
Updated: 7/9/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
2315
mi
from 98109
Bethesda, MD
Click here to add this to my saved trials
Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir
A Phase 1, Single-center, Randomized, Open-label, Crossover Study to Assess the Relative Bioavailability of Phase III Tablet Formulation Candidates in Healthy Adult Subjects
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
1504
mi
from 98109
Overland Park, KA
Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir
A Phase 1, Single-center, Randomized, Open-label, Crossover Study to Assess the Relative Bioavailability of Phase III Tablet Formulation Candidates in Healthy Adult Subjects
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
1504
mi
from 98109
Overland Park, KA
Click here to add this to my saved trials
Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects
A Pilot Study to Assess Virologic Suppression and Immune Recovery With Raltegravir and Lopinavir/Ritonavir and Raltegravir and Emtricitabine/Tenofovir in HIV-1 Infected Treatment-naïve Subjects
Status: Enrolling
Updated:  7/11/2015
University of Miami AIDS Clinical Research Unit
2730
mi
from 98109
Miami, FL
Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects
A Pilot Study to Assess Virologic Suppression and Immune Recovery With Raltegravir and Lopinavir/Ritonavir and Raltegravir and Emtricitabine/Tenofovir in HIV-1 Infected Treatment-naïve Subjects
Status: Enrolling
Updated: 7/11/2015
University of Miami AIDS Clinical Research Unit
2730
mi
from 98109
Miami, FL
Click here to add this to my saved trials
Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection
Pilot Study of Raltegravir/Tenofovir/Emtricitabine Versus Efavirenz/Tenofovir/Emtricitabine for Adults With Acute HIV-1 Infection: Exploring the Role of Integrase Inhibition in Early HIV Pathogenesis
Status: Enrolling
Updated:  7/11/2015
UAB 1917 Clinic
2072
mi
from 98109
Birmingham, AL
Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection
Pilot Study of Raltegravir/Tenofovir/Emtricitabine Versus Efavirenz/Tenofovir/Emtricitabine for Adults With Acute HIV-1 Infection: Exploring the Role of Integrase Inhibition in Early HIV Pathogenesis
Status: Enrolling
Updated: 7/11/2015
UAB 1917 Clinic
2072
mi
from 98109
Birmingham, AL
Click here to add this to my saved trials
Improving Drug Adherence Among Adolescents in Uganda Using SMS Reminders
Improving Drug Adherence Among Adolescents in Uganda Using SMS Reminders
Status: Enrolling
Updated:  7/14/2015
RAND
979
mi
from 98109
Santa Monica, CA
Improving Drug Adherence Among Adolescents in Uganda Using SMS Reminders
Improving Drug Adherence Among Adolescents in Uganda Using SMS Reminders
Status: Enrolling
Updated: 7/14/2015
RAND
979
mi
from 98109
Santa Monica, CA
Click here to add this to my saved trials
Improving Drug Adherence Among Adolescents in Uganda Using SMS Reminders
Improving Drug Adherence Among Adolescents in Uganda Using SMS Reminders
Status: Enrolling
Updated:  7/14/2015
Infectious Diseases Institute
8794
mi
from 98109
Kampala,
Improving Drug Adherence Among Adolescents in Uganda Using SMS Reminders
Improving Drug Adherence Among Adolescents in Uganda Using SMS Reminders
Status: Enrolling
Updated: 7/14/2015
Infectious Diseases Institute
8794
mi
from 98109
Kampala,
Click here to add this to my saved trials
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status: Enrolling
Updated:  7/14/2015
Clinical Research Facility
979
mi
from 98109
Long Beach, CA
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status: Enrolling
Updated: 7/14/2015
Clinical Research Facility
979
mi
from 98109
Long Beach, CA
Click here to add this to my saved trials
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status: Enrolling
Updated:  7/14/2015
Clinical Research Facility
999
mi
from 98109
Palm Springs, CA
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status: Enrolling
Updated: 7/14/2015
Clinical Research Facility
999
mi
from 98109
Palm Springs, CA
Click here to add this to my saved trials
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status: Enrolling
Updated:  7/14/2015
Clinical Research Facility
681
mi
from 98109
San Francisco, CA
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status: Enrolling
Updated: 7/14/2015
Clinical Research Facility
681
mi
from 98109
San Francisco, CA
Click here to add this to my saved trials
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status: Enrolling
Updated:  7/14/2015
Clinical Research Facility
2416
mi
from 98109
Norwalk, CT
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status: Enrolling
Updated: 7/14/2015
Clinical Research Facility
2416
mi
from 98109
Norwalk, CT
Click here to add this to my saved trials
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status: Enrolling
Updated:  7/14/2015
Clinical Research Facility
2322
mi
from 98109
Washington,
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status: Enrolling
Updated: 7/14/2015
Clinical Research Facility
2322
mi
from 98109
Washington,
Click here to add this to my saved trials
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status: Enrolling
Updated:  7/14/2015
Clinical Research Facility
2544
mi
from 98109
Orlando, FL
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status: Enrolling
Updated: 7/14/2015
Clinical Research Facility
2544
mi
from 98109
Orlando, FL
Click here to add this to my saved trials
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status: Enrolling
Updated:  7/14/2015
Clinical Research Facility
2400
mi
from 98109
New York, NY
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status: Enrolling
Updated: 7/14/2015
Clinical Research Facility
2400
mi
from 98109
New York, NY
Click here to add this to my saved trials
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status: Enrolling
Updated:  7/14/2015
Clinical Research Facility
2400
mi
from 98109
New York, NY
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status: Enrolling
Updated: 7/14/2015
Clinical Research Facility
2400
mi
from 98109
New York, NY
Click here to add this to my saved trials
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status: Enrolling
Updated:  7/14/2015
Clinical Research Facility
1775
mi
from 98109
Austin, TX
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status: Enrolling
Updated: 7/14/2015
Clinical Research Facility
1775
mi
from 98109
Austin, TX
Click here to add this to my saved trials
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status: Enrolling
Updated:  7/14/2015
Clinical Research Facility
1682
mi
from 98109
Dallas, TX
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning
Status: Enrolling
Updated: 7/14/2015
Clinical Research Facility
1682
mi
from 98109
Dallas, TX
Click here to add this to my saved trials
Stanford Universities: The Stanford HIV Aging Cohort
The Stanford HIV Aging Cohort (SHAC)
Status: Enrolling
Updated:  7/15/2015
Stanford University School of Medicine
705
mi
from 98109
Stanford, CA
Stanford Universities: The Stanford HIV Aging Cohort
The Stanford HIV Aging Cohort (SHAC)
Status: Enrolling
Updated: 7/15/2015
Stanford University School of Medicine
705
mi
from 98109
Stanford, CA
Click here to add this to my saved trials
Accuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts
Clinical Evaluation of the Accuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts
Status: Enrolling
Updated:  7/20/2015
Fenway Community Health
2485
mi
from 98109
Boston, MA
Accuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts
Clinical Evaluation of the Accuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts
Status: Enrolling
Updated: 7/20/2015
Fenway Community Health
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Accuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts
Clinical Evaluation of the Accuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts
Status: Enrolling
Updated:  7/20/2015
Univ of North Carolina
2337
mi
from 98109
Chapel Hill, NC
Accuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts
Clinical Evaluation of the Accuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts
Status: Enrolling
Updated: 7/20/2015
Univ of North Carolina
2337
mi
from 98109
Chapel Hill, NC
Click here to add this to my saved trials
Accuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts
Clinical Evaluation of the Accuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts
Status: Enrolling
Updated:  7/20/2015
Miriam Hospital
2486
mi
from 98109
Providence, RI
Accuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts
Clinical Evaluation of the Accuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts
Status: Enrolling
Updated: 7/20/2015
Miriam Hospital
2486
mi
from 98109
Providence, RI
Click here to add this to my saved trials
Effectiveness of Structured Ecosystems Therapy for Reducing HIV Risk Behaviors and Improving Treatment Adherence in HIV Infected Men Released From Prison
Ecosystems Therapy for Men Reintegrating Into Their Family
Status: Enrolling
Updated:  7/22/2015
University of California at San Francisco
682
mi
from 98109
San Francisco, CA
Effectiveness of Structured Ecosystems Therapy for Reducing HIV Risk Behaviors and Improving Treatment Adherence in HIV Infected Men Released From Prison
Ecosystems Therapy for Men Reintegrating Into Their Family
Status: Enrolling
Updated: 7/22/2015
University of California at San Francisco
682
mi
from 98109
San Francisco, CA
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience
Phase IIIb/IV Randomized, Controlled Study Evaluating an Intensification Treatment Strategy of Adding Enfuvirtide (ENF) to an Oral Highly Active AntiRetroviral Therapy (HAART) in Treatment Experienced Patients
Status: Enrolling
Updated:  7/22/2015
Clinical Research Facility
2020
mi
from 98109
Cleveland, OH
A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience
Phase IIIb/IV Randomized, Controlled Study Evaluating an Intensification Treatment Strategy of Adding Enfuvirtide (ENF) to an Oral Highly Active AntiRetroviral Therapy (HAART) in Treatment Experienced Patients
Status: Enrolling
Updated: 7/22/2015
Clinical Research Facility
2020
mi
from 98109
Cleveland, OH
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience
Phase IIIb/IV Randomized, Controlled Study Evaluating an Intensification Treatment Strategy of Adding Enfuvirtide (ENF) to an Oral Highly Active AntiRetroviral Therapy (HAART) in Treatment Experienced Patients
Status: Enrolling
Updated:  7/22/2015
Clinical Research Facility
1775
mi
from 98109
Austin, TX
A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience
Phase IIIb/IV Randomized, Controlled Study Evaluating an Intensification Treatment Strategy of Adding Enfuvirtide (ENF) to an Oral Highly Active AntiRetroviral Therapy (HAART) in Treatment Experienced Patients
Status: Enrolling
Updated: 7/22/2015
Clinical Research Facility
1775
mi
from 98109
Austin, TX
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience
Phase IIIb/IV Randomized, Controlled Study Evaluating an Intensification Treatment Strategy of Adding Enfuvirtide (ENF) to an Oral Highly Active AntiRetroviral Therapy (HAART) in Treatment Experienced Patients
Status: Enrolling
Updated:  7/22/2015
Clinical Research Facility
1682
mi
from 98109
Dallas, TX
A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience
Phase IIIb/IV Randomized, Controlled Study Evaluating an Intensification Treatment Strategy of Adding Enfuvirtide (ENF) to an Oral Highly Active AntiRetroviral Therapy (HAART) in Treatment Experienced Patients
Status: Enrolling
Updated: 7/22/2015
Clinical Research Facility
1682
mi
from 98109
Dallas, TX
Click here to add this to my saved trials